Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Current Assets (2016 - 2026)

Corvus Pharmaceuticals' Current Assets history spans 12 years, with the latest figure at $239.9 million for Q1 2026.

  • Quarterly Current Assets rose 427.46% to $239.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $239.9 million through Mar 2026, up 427.46% year-over-year, with the annual reading at $58.2 million for FY2025, 7.0% up from the prior year.
  • Current Assets came in at $239.9 million for Q1 2026, up from $58.2 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $239.9 million in Q1 2026 to a low of $22.9 million in Q1 2024.
  • The 5-year median for Current Assets is $48.3 million (2024), against an average of $59.3 million.
  • Year-over-year, Current Assets plummeted 44.77% in 2023 and then skyrocketed 427.46% in 2026.
  • Corvus Pharmaceuticals' Current Assets stood at $43.7 million in 2022, then plummeted by 35.97% to $28.0 million in 2023, then surged by 94.62% to $54.4 million in 2024, then rose by 7.0% to $58.2 million in 2025, then soared by 312.18% to $239.9 million in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Current Assets are $239.9 million (Q1 2026), $58.2 million (Q4 2025), and $66.9 million (Q3 2025).